Sirolimus-eluting collagen implant for preventing vascular access failure in end stage renal disease patients undergoing haemodialysis


featured image

Sirolimus-eluting collagen implant is in clinical development for prevention of arteriovenous (AV) vascular access dysfunction in patients with end stage renal disease (ESRD) who are undergoing haemodialysis.

Indications: Renal disease
Therapeutic Areas: Cardiovascular System , Immunology
Year: 2023

Sirolimus-eluting collagen implant is in clinical development for prevention of arteriovenous (AV) vascular access dysfunction in patients with end stage renal disease (ESRD) who are undergoing haemodialysis. ESRD, also known as stage 5 chronic kidney disease (CKD) require either a kidney transplant or dialysis to remove excess fluid and waste products from the blood when their kidneys no longer work properly. Haemodialysis is a procedure where the blood is taken from the patient, filtered and cleaned by a dialysis machine, and then returned to the patient. In order to facilitate haemodialysis, surgery to connect an artery and vein is required for vascular access. However, vascular access failure or dysfunction is common and is an important unmet medical need.